{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:11:37Z","timestamp":1792894297104,"version":"4.5.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Kidney function is usually estimated from serum creatinine level, whereas an alternative glomerular filtration marker (cystatin C level) associates more closely with future risk of cardiovascular disease (CVD) and mortality.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To evaluate whether testing concordance between estimated glomerular filtration rates based on cystatin C (eGFRcys) and creatinine (eGFRcr) levels would improve risk stratification for future outcomes and whether estimations differ by age.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A prospective population-based cohort study (UK Biobank), with participants recruited between 2006-2010 with median follow-up of 11.5 (IQR, 10.8-12.2) years; data were collected until August 31, 2020. Participants had eGFRcr greater than or equal to 45 mL\/min\/1.73 m2<\/jats:sup>, albuminuria (albumin &amp;lt;30 mg\/g), and no preexisting CVD or kidney failure.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Chronic kidney disease status was categorized by concordance between eGFRcr and eGFRcys across the threshold for hronic kidney disease (CKD) diagnosis (60 mL\/min\/1.73 m2<\/jats:sup>).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Ten-year probabilities of CVD, mortality, and kidney failure were assessed according to CKD status. Multivariable-adjusted Cox proportional hazards models tested associations between CVD and mortality. Area under the receiving operating curve tested discrimination of eGFRcr and eGFRcys for CVD and mortality. The Net Reclassification Index assessed the usefulness of eGFRcr and eGFRcys for CVD risk stratification. Analyses were stratified by older (age 65-73 years) and younger (age &amp;lt;65 years) age.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 428\u202f402 participants: median age was 57 (IQR, 50-63) years and 237 173 (55.4%) were women. Among 76\u202f629 older participants, there were 9335 deaths and 5205 CVD events. Among 351\u202f773 younger participants, there were 14\u202f776 deaths and 9328 CVD events. The 10-year probability of kidney failure was less than 0.1%. Regardless of the eGFRcr, the 10-year probabilities of CVD and mortality were low when eGFRcys was greater than or equal to 60 mL\/min\/1.73 m2<\/jats:sup>; conversely, with eGFRcys less than 60 mL\/min\/1.73 m2<\/jats:sup>, 10-year risks were nearly doubled in older adults and more than doubled in younger adults. Use of eGFRcys better discriminated CVD and mortality risk than eGFRcr. Across a 7.5% 10-year risk threshold for CVD, eGFRcys improved case Net Reclassification Index by 0.7% (95% CI, 0.6%-0.8%) in older people and 0.7% (95% CI, 0.7%-0.8%) in younger people; eGFRcr did not add to CVD risk estimation.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this study suggest that eGFRcr 45 to 59 mL\/min\/1.73 m2<\/jats:sup> includes a proportion of individuals at low risk and fails to capture a substantial proportion of individuals at high-risk for CVD and mortality. The eGFRcys appears to be more sensitive and specific for CVD and mortality risks in mild CKD.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.38300","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T15:03:38Z","timestamp":1666710218000},"page":"e2238300","source":"Crossref","is-referenced-by-count":57,"title":["Assessment of Cystatin C Level for Risk Stratification in Adults With Chronic Kidney Disease"],"prefix":"10.1001","volume":"5","author":[{"given":"Jennifer S.","family":"Lees","sequence":"first","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom"},{"name":"Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Rutherford","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom"},{"name":"Renal Unit, Mountainhall Treatment Centre, NHS Dumfries and Galloway, Dumfries, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn I.","family":"Stevens","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom"},{"name":"Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Kidney Health Research Collaborative, Department of Medicine, University of California San Francisco and San Francisco VA Health Care System, San Francisco"},{"name":"Genentech\/Roche, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Scherzer","sequence":"additional","affiliation":[{"name":"Kidney Health Research Collaborative, Department of Medicine, University of California San Francisco and San Francisco VA Health Care System, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Estrella","sequence":"additional","affiliation":[{"name":"Kidney Health Research Collaborative, Department of Medicine, University of California San Francisco and San Francisco VA Health Care System, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom"},{"name":"Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ebert","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Charit\u00e9 University Hospital, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Mark","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom"},{"name":"Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Shlipak","sequence":"additional","affiliation":[{"name":"Kidney Health Research Collaborative, Department of Medicine, University of California San Francisco and San Francisco VA Health Care System, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"issue":"1","key":"zoi221084r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Kidney Disease Working Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"zoi221084r2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.16631221","article-title":"Age and the course of GFR in persons aged 70 and above.","author":"Schaeffner","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"zoi221084r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100662","article-title":"How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy.","volume":"29-30","author":"Nankivell","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"6","key":"zoi221084r4","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/jcsm.v10.6","article-title":"The Copenhagen Sarcopenia Study: lean mass, strength, power, and physical function in a Danish cohort aged 20-93 years.","volume":"10","author":"Suetta","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"zoi221084r5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/s41591-019-0627-8","article-title":"Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease.","volume":"25","author":"Lees","year":"2019","journal-title":"Nat Med"},{"issue":"10","key":"zoi221084r6","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function.","volume":"369","author":"Shlipak","year":"2013","journal-title":"N Engl J Med"},{"issue":"663","key":"zoi221084r7","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.3399\/bjgp17X692585","article-title":"Requirement for cystatin C testing in chronic kidney disease: a retrospective population-based study.","volume":"67","author":"Lasserson","year":"2017","journal-title":"Br J Gen Pract"},{"key":"zoi221084r8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.hlpt.2012.07.003","article-title":"UK Biobank: current status and what it means for epidemiology.","volume":"1","author":"Allen","year":"2012","journal-title":"Health Policy Technol"},{"issue":"2","key":"zoi221084r10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ije\/dym276","article-title":"The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine.","volume":"37","author":"Elliott","year":"2008","journal-title":"Int J Epidemiol"},{"issue":"19","key":"zoi221084r13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi221084r14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi221084r15","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1056\/NEJMoa2103753","article-title":"Race, genetic ancestry, and estimating kidney function in CKD.","volume":"385","author":"Hsu","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi221084r16","first-page":"S49","article-title":"ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines.","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"zoi221084r19","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1681\/ASN.2019030238","article-title":"CKD: a call for an age-adapted definition.","volume":"30","author":"Delanaye","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"zoi221084r20","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1001\/jama.2011.468","article-title":"Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.","volume":"305","author":"Peralta","year":"2011","journal-title":"JAMA"},{"issue":"22","key":"zoi221084r21","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2012.16817","article-title":"Age and association of kidney measures with mortality and end-stage renal disease.","volume":"308","author":"Hallan","year":"2012","journal-title":"JAMA"},{"issue":"9731","key":"zoi221084r22","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"zoi221084r23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.ajkd.2020.09.015","article-title":"Kidney function as risk factor and predictor of cardiovascular outcomes and mortality among older adults.","volume":"77","author":"K\u00fchn","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"zoi221084r24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jamainternmed.2021.4813","article-title":"Accounting for age in the definition of chronic kidney disease.","volume":"181","author":"Liu","year":"2021","journal-title":"JAMA Intern Med"},{"key":"zoi221084r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets.","volume":"27","author":"Matsushita","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10","key":"zoi221084r27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"zoi221084r28","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1161\/CIRCULATIONAHA.121.057631","article-title":"Beyond ten-year risk: a cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease.","volume":"145","author":"Kohli-Lynch","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"zoi221084r29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1056\/NEJMc2032809","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"384","author":"Vogt","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi221084r30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.34067\/KID.0003912021","article-title":"Albuminuria within the normal range can predict all-cause mortality and cardiovascular mortality.","volume":"3","author":"Kang","year":"2021","journal-title":"Kidney360"},{"issue":"11","key":"zoi221084r31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002955","article-title":"The Kidney Failure Risk Equation for prediction of end stage renal disease in UK primary care: an external validation and clinical impact projection cohort study.","volume":"16","author":"Major","year":"2019","journal-title":"PLoS Med"},{"issue":"2","key":"zoi221084r32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis.","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"zoi221084r33","doi-asserted-by":"publisher","DOI":"10.1177\/2054358117705372","article-title":"Validation of the Kidney Failure Risk Equation in Manitoba.","volume":"4","author":"Whitlock","year":"2017","journal-title":"Can J Kidney Health Dis"},{"issue":"3","key":"zoi221084r34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M21-2928","article-title":"Prediction of end-stage kidney disease using estimated glomerular filtration rate with and without race: a prospective cohort study.","volume":"175","author":"Bundy","year":"2022","journal-title":"Ann Intern Med"},{"key":"zoi221084r35","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(13)61420-5","article-title":"Association of cystatin C with measures of obesity and its impact on cardiovascular events among healthy US adults.","volume":"61","author":"Panaich","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"23-24","key":"zoi221084r36","first-page":"339","article-title":"Effects of thyroxine replacement on serum creatinine and cystatin C in patients with primary and central hypothyroidism.","volume":"139","author":"Goede","year":"2009","journal-title":"Swiss Med Wkly"},{"issue":"6","key":"zoi221084r37","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/ki.2013.7","article-title":"Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease.","volume":"83","author":"Rule","year":"2013","journal-title":"Kidney Int"},{"issue":"2","key":"zoi221084r38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.ajkd.2012.04.012","article-title":"Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study.","volume":"60","author":"Anderson","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"zoi221084r39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/13539.2190-6009","article-title":"Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature.","volume":"4","author":"Patel","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"zoi221084r40","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2215\/CJN.02870707","article-title":"Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C.","volume":"3","author":"Baxmann","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"zoi221084r42","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac241","article-title":"Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil, and Africa.","author":"Delanaye","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"zoi221084r43","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population.","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"},{"key":"zoi221084r44","doi-asserted-by":"publisher","first-page":"m131","DOI":"10.1136\/bmj.m131","article-title":"Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis.","volume":"368","author":"Batty","year":"2020","journal-title":"BMJ"},{"key":"zoi221084r9","unstructured":"UK Biobank. Protocol for a large-scale prospective epidemiological resource. March 21, 2007. Accessed September 10, 2022. https:\/\/www.ukbiobank.ac.uk\/media\/gnkeyh2q\/study-rationale.pdf"},{"key":"zoi221084r11","unstructured":"UK Biobank Showcase. Blood sample collection, processing and transport. 2011. Accessed April 17, 2019. https:\/\/biobank.ctsu.ox.ac.uk\/showcase\/docs\/Bloodsample.pdf"},{"key":"zoi221084r12","unstructured":"UK Biobank Showcase. Biospeciments manual: collection of biological samples, processing and storage. 2011. Accessed April 17, 2019. https:\/\/biobank.ctsu.ox.ac.uk\/crystal\/docs\/BioSampleProc.pdf"},{"key":"zoi221084r17","unstructured":"UK Biobank. Algorithmically-defined health outcomes. January 2022. Accessed September 24, 2021. https:\/\/biobank.ndph.ox.ac.uk\/showcase\/showcase\/docs\/alg_outcome_main.pdf"},{"key":"zoi221084r18","unstructured":"Bush? K, Nolan? J, Zhang? Q, Herrington? W, Sudlow? C; UK Biobank Outcome Adjudication Group. Definitions of end stage renal disease for UK Biobank phase 1 outcomes adjudication. January 2022. Accessed September 10, 2022. https:\/\/biobank.ndph.ox.ac.uk\/ukb\/ukb\/docs\/alg_outcome_esrd.pdf"},{"key":"zoi221084r25","unstructured":"Kidney International Supplements. Definition and classification of CKD. January 2013. Accessed September 10, 2022. https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO_2012_CKD_GL.pdf"},{"key":"zoi221084r41","unstructured":"National Institute for Health and Care Excellence. Costing statement: chronic kidney disease: implementing the NICE guideline on chronic kidney disease. July 23, 2014. Accessed September 10, 2022. http:\/\/www.nice.org.uk\/guidance\/cg182\/resources\/cg182-chronic-kidney-disease-update-costing-statement2"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797627\/lees_2022_oi_221084_1666016871.55402.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T15:03:48Z","timestamp":1666710228000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.38300","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}